Michel Fortin, President & Chief Executive Officer
As founder of EVAH, Michel has over 15 years of experience in animal health as past CEO of Prevtec Microbia. He is a seasoned entrepreneur, an excellent developer and promoter who is recognized for his creative strategic thinking and his flair for identifying opportunities and his ability to raise the capital to fulfill them. Over the last 30 years, Michel has a good track record of financing and merger and acquisitions deals thanks to his outstanding communication skills, which he displays during negotiations and during public speaking engagements. He is a CPA, CA, and has completed the Directors Education Program of the Institute of Corporate Directors, at University of Toronto’s Rotman School of Management. Michel is Past President of BIOQuébec, the trade association of Québec life sciences companies, and he sits on the Board of Génome Québec.
Nicole Blanchard, COO
As co-founder of EVAH, Nicole brings 30 years of global business experience. She has 15 years of experience in advisory roles to c-suite executives from public and private corporations. For instance, she worked with Michel Fortin at Prevtec Microbia, an animal health biotechnology company, on raising capital internationally. For 15 years before that, she was a senior executive in charge of corporate strategy and corporate communications, a spokesperson, and an Investor Relations Officer for dual-listed public companies across several industry sectors such as biotechnology, telecom and financial services. Nicole has earned two undergraduate degrees from Concordia University, in Sciences and International Business.
Erika Tremblay-Gagnon, CFO
Erika has more than 15 years of experience in finance and management. She is an experienced leader with the ability to motivate teams under demanding working conditions, having achieved success in several special projects, ranging from initial public offerings to Canadian and international tax compliance dossiers and business acquisitions and integration. Prior to forming her advisory firm Gagnon Miquelon, she was Vice-President at Stingray for five years, supervising 16 people in corporate and operational finance. Previously, she was Senior Audit Manager at PwC for 10 years. Erika is a C.A. and has a master’s degree from Université de Sherbrooke.
Louise Bélanger, Director R&D
Louise is a creative leader at EVAH, supervising all research and development (R&D) activities. She is focused on developing innovative products as alternatives to antibiotics in animal health. Louise previously worked as Research Scientist and later as Principal Scientist at Prevtec Microbia from 2012 to 2020, where she directed laboratory activities for R&D and clinical trials. She also collaborated with universities and contract research organizations to manage the R&D process and developed innovative technologies. She did her postdoctoral fellowship in collaboration with the Institut national de la recherche scientifique and Université de Montréal in 2012 and received an Industrial R&D Fellowship from the Natural Sciences and Engineering Research Council of Canada in 2010. Louise has a PhD Microbiology from University of Waterloo, an MSc. Microbiology from McGill University and a B.Sc. Biochemistry from Université du Québec à Montréal.
Board of Directors
Frédéric Beaulac, DVM
A doctor in Veterinary Medicine, Frédéric has 20 years of experience as a consulting veterinarian in private practice for production animals, namely swine, veal, beef and lamb. He also has experience in community pharmacy. He is currently co-owner of the Triple-V veterinary clinic, a team of 13 veterinarians providing services to producers and integrators in the hog, avian, sheep, rabbit and beef cattle sectors from Québec and eastern Ontario. He is also co-owner of Canadian Livestock Veterinarians, a group managing swine, avian and beef cattle veterinary clinics in Alberta, Manitoba, Ontario, Québec and Nova Scotia. Previously, Frédéric was co-owner of a veterinary pharmacy for 13 years. He earned a degree in Pharmacy from Université de Montréal and a doctorate in veterinary medicine from Université de Montréal.
Pierre Falardeau, Ph.D.
Pierre is a doctor in pharmacology with more than 20 years of experience in the biotech industry, raising hundreds of millions of dollars in capital and conducting mergers and acquisitions and partnerships. Most recently, Pierre held the position of Chief Innovation Officer at Bio-K Plus International. Previously, he was President and CEO of Verlyx Pharma and prior to that, President and CEO of Ecopia Biosciences. Before joining Ecopia, Pierre was vice president of scientific affairs at Aeterna (now Aeterna-Zentaris). Pierre was Associate Professor at the Faculty of Pharmacy at Université Laval in Québec after spending five years at the Howard Hugues Medical Institute at Duke University in North Carolina with Drs. Marc Caron and Robert Lefkowitz (Nobel Prize in Chemistry in 2012). He is currently a strategic consultant actively involved in the biotech sector, and serves on the boards of directors of BIOQuébec and Montréal InVivo.
Martin is co-founder and CEO of CellCarta Biosciences, a leader in specialized precision medicine laboratory services for the biopharmaceutical industry that operates globally with over 700 employees in nine facilities across Canada, the United States, Belgium, Australia and China. Under Martin’s leadership, CellCarta has sustained strong organic growth, concluded nine mergers and acquisitions, and successively came under the ownership of four leading healthcare private equity firms. Martin is also the Chairman of the Board of Montréal InVivo and sits on the board of numerous private companies and not-for-profit organizations. Previously, Martin was a management consultant for McKinsey & Company, as well as co-owner and senior executive of another successful biotech venture, Advanced Bioconcept. Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.
Brian M. Levitt
Brian is an Officer of the Order of Canada and a Fellow of the Institute of Corporate Directors. He is currently the non-executive independent Board Chair of TD Bank Group and serves on the Board of Directors of The Charles Schwab Corporation. From 1991 to 2000, he was President and Chief Executive Officer of Imasco Limited, a Canadian consumer goods and services company. Brian previously served in various executive and non-executive leadership positions at the law firm Osler, Hoskin & Harcourt LLP. He holds a law degree from the University of Toronto, where he also completed his Bachelor of Applied Science degree in Civil Engineering.
Michel Fortin, President & Chief Executive Officer
Nicole Blanchard, COO
Martin Izquierdo Moreno, Observer
Martin Izquierdo Moreno is Managing Director Corporate Development at Grupo Fuertes with more than 15 years of experience in Investments, M&A and Strategy. Grupo Fuertes is a Spanish leader conglomerate in AgriFood, with more than 20 strategically organized companies in a powerful AgriFood core business and a diversified portfolio of investments. Martin has a doctorate in Economy and an Executive MBA from ENAE Business School.